Johnson & Johnson

Intellect Neurosciences to appeal in European patent proceedings

Wednesday, February 15, 2012 03:30 PM

Intellect Neurosciences, a biopharmaceutical company focused on disease-modifying therapeutic agents for Alzheimer's disease, submitted a statement setting out its grounds for appealing the European Patent Office's (EPO) preliminary decision to revoke the company's Antisenilin (bapineuzumab) patents.

More... »

Dendreon announces CEO and chairman succession plan

Wednesday, February 1, 2012 03:41 PM

Dendreon’s board of directors has elected John H. Johnson president and CEO, succeeding Mitchell H. Gold, M.D., who has served as both for nearly a decade.

More... »

International collaboration to combat 10 neglected tropical diseases by 2020

Monday, January 30, 2012 03:49 PM

Thirteen pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organizations will join forces to eliminate or control 10 neglected tropical diseases (NTDs) by the end of the decade.

More... »

FDA holds J&J under magnifying glass

Friday, January 13, 2012 01:34 PM

The FDA has trained a watchful eye on Johnson & Johnson as delayed reports, recalls and court trials pile up.

More... »

J&J closes Quebec research center

Wednesday, January 11, 2012 01:12 PM

Johnson & Johnson is closing its Quebec research center, according to a news report on Canada.com.

More... »

Forma and Janssen to collaborate on cancer drug

Wednesday, January 11, 2012 11:19 AM

Forma Therapeutics has formed an exclusive alliance with Janssen Biotech (a subsidiary of Johnson & Johnson), in which the pair will collaborate on discovery, development and commercialization of novel small molecule drug candidates that target tumor metabolism mechanisms.

More... »

Giant leap for HIV cure

Wednesday, January 11, 2012 11:09 AM

After 30 years of unsuccessful attempts, an HIV vaccine may be within reach. That’s what scientists at Crucell NV of the Netherlands (a subsidiary of Johnson & Johnson) are saying.

More... »

Johnson & Johnson halts Doribax trial due to ‘significant safety concerns’

Monday, January 9, 2012 09:20 AM

Johnson & Johnson shut down a clinical trial of antibiotic Doribax after causing excess mortality and a numerically poorer cure rate than pneumonia subjects treated with imipenem-cilastatin, the generic version of Merck’s Primaxin.

More... »

Janssen, Pharmacyclics collaborate to develop anti-cancer drug

Friday, December 9, 2011 07:56 AM

Janssen Biotech, one of the Janssen Pharmaceutical companies of Johnson & Johnson, has executed an agreement with Pharmacyclics to jointly develop and market the anti-cancer compound, PCI-32765. A number of phase I and II studies with PCI-32765 are ongoing across a panel of B-cell malignancy disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.

More... »

Synexus exceeds expectations in clinical trial recruitment

Tuesday, October 25, 2011 01:53 PM

Synexus’ Pretoria clinical research center has enrolled more patients than any other site across the world in a type 2 diabetes trial for Janssen Pharmaceuticals.

More... »